05/16/2024

Hepatitis C Educational Webinar for Prescribers Scheduled for June 13

Background:

Mavyret manufacturer AbbVie is hosting an educational event for prescribers regarding Hepatitis C.


Key Details:

In support of the HHSC initiative to improve awareness, screening, diagnosis, and treatment of the Hepatitis C Virus for Medicaid clients, AbbVie will host an educational event for prescribers called *Treating Hepatitis C In Your Practice* on June 13. Registration ends June 8. PCHP encourages INN Prescribers attend this event.

- Thursday, June 13, 2024
- 12:15 p.m., central time
- To register, go to myattendeeresource.com/AbbVie/240613-Abbvie-3818.

Resources:

061324 HCV program KimHinojosa.pdf (attached)





Kim Hinojosa, CNP
Health Outcomes Center

Kim Hinojosa, RN, BSN, MSN, FNP-C, received her Master's degree in Nursing from The University of Texas Health Science Center at San Antonio in 2010, and her Bachelor of Science in Nursing from the St. Josephs College in 1998. She is board certified with the American Academy of Nurse Practitioners (AANP). She worked in a busy family practice setting for five years and began working with Hepatitis C patients in 2016.



DATE & TIME: Thursday, June 13, 2024 12:15 PM



LOCATION:
Virtual Location
190 Main St
Gladstone, New Jersey 07934



PLEASE RSVP BY: June 8, 2024

RSVP to Marisela Padilla at marisela.padilla@abbvie.com or (318) 294-0850

https://myattendeeresource.com/AbbVie/240613-Abbvie-3818

In accordance with the PhRMA Code on Interactions with Healthcare Professionals, attendance at this program is limited to healthcare professionals who practice relevant specialties.

AbbVie tracks and reports payments and transfers of value to healthcare professionals under applicable state and federal reporting obligations.

Alcohol will no longer be provided by AbbVie at programs.



INDICATION

MAVYRET is indicated for the treatment of adult and pediatric patients 3 years and older with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A). MAVYRET is indicated for the treatment of adult and pediatric patients 3 years and older with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor (PI), but not both.

IMPORTANT SAFETY INFORMATION

WARNING: RISK OF HEPATITIS B VIRUS REACTIVATION IN PATIENTS COINFECTED WITH HCV AND HBV: Test all patients for evidence of current or prior hepatitis B virus (HBV) infection before initiating treatment with MAVYRET. HBV reactivation has been reported in HCV/HBV coinfected patients who were undergoing or had completed treatment with HCV direct-acting antivirals and were not receiving HBV antiviral therapy. Some cases have resulted in fulminant hepatitis, hepatic failure, and death. Monitor HCV/HBV coinfected patients for hepatitis flare or HBV reactivation during HCV treatment and posttreatment follow-up. Initiate appropriate patient management for HBV infection as clinically indicated.

CONTRAINDICATIONS

- MAVYRET is contraindicated in patients with moderate or severe hepatic impairment (Child-Pugh B or C) or those with any history of prior hepatic decompensation.
- MAVYRET is contraindicated with atazanavir or rifampin.

WARNINGS AND PRECAUTIONS

Risk of Hepatic Decompensation/Failure in Patients with Evidence of Advanced Liver Disease

· Postmarketing cases of hepatic decompensation/failure, some fatal, have been reported in patients treated with HCV NS3/4A protease inhibitor-containing regimens, including MAVYRET. The median time to onset for MAVYRET was 27 days. The majority had moderate or severe hepatic impairment prior to initiating therapy, including some with compensated cirrhosis at baseline but with a prior decompensation event. Rare cases were reported in patients without cirrhosis or with compensated cirrhosis; many of these patients had evidence of portal hypertension. In patients with compensated cirrhosis or evidence of advanced liver disease, perform hepatic laboratory testing as clinically indicated; and monitor for signs and symptoms of hepatic decompensation, such as the presence of jaundice, ascites, hepatic encephalopathy, and variceal hemorrhage. Discontinue MAVYRET in patients who develop evidence of hepatic decompensation/failure.

Risk of Reduced Therapeutic Effect Due to Concomitant Use of MAVYRET with Certain Drugs

 Carbamazepine, efavirenz, and St. John's Wort may significantly decrease plasma concentrations of glecaprevir and pibrentasvir, leading to reduced therapeutic effect of MAVYRET. The use of these agents with MAVYRET is not recommended.

ADVERSE REACTIONS

Most common adverse reactions observed with MAVYRET:

· >10% of subjects: headache and fatigue

MAVYRET oral pellets are dispensed in unit-dose packets. Each packet contains 50 mg glecaprevir/20 mg pibrentasvir.

Please see accompanying full <u>Prescribing Information</u> or at <u>www.rxabbvie.com/pdf/mavyret_pi.pdf</u>

Reference: MAVYRET [package insert]. North Chicago, IL; AbbVie Inc.

© 2023 AbbVie. All rights reserved.

US-MAVY-230117 July 2023 240613-MAV-3818

